All In MedTech

FDA Clearance Tracker · P150021

FREESTYLE LIBRE PRO FLASH GLUCOSE MONITORING SYSTEM

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Sep 23, 2016 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Sep 23, 2016

Approved

Time to decision

462 days

Received Jun 19, 2015. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P150021
Device name
FREESTYLE LIBRE PRO FLASH GLUCOSE MONITORING SYSTEM
Applicant location
Alameda, CA
Received
Jun 19, 2015
Decided
Sep 23, 2016
Decision
Approved
Supplements
59 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code MDS

FDA's approval statement

As written in FDA's record.

The FreeStyle Libre Pro Flash Glucose Monitoring System is a professional continuous glucose monitoring (CGM) device indicated for detecting trends and tracking patterns in persons (age 18 and older) with diabetes. The System is intended for use by health care professionals and requires a prescription. Readings from the FreeStyle Libre Pro Sensor are only made available to patients through consultation with a health care professional. The System does not require user calibration with blood glucose values.The FreeStyle Libre Pro System aids in the detection of glucose level excursions above or below the desired range, facilitating therapy adjustments. Interpretation of the FreeStyle Libre Pro Flash Glucose Monitoring System readings should be based on the trends and patterns analyzed through time using the reports available.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code MDS. The earliest in FDA's data is P980022, decided Jun 15, 1999.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Abbott Diabetes Care, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.